4//SEC Filing
CoLucid Pharmaceuticals, Inc. 4
Accession 0000911916-17-000078
CIK 0001348649operating
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 12:22 PM ET
Size
15.1 KB
Accession
0000911916-17-000078
Insider Transaction Report
Form 4
Mathers Thomas P.
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2017-03-01$36.50/sh−360,508$13,158,542→ 0 totalExercise: $10.00Exp: 2025-05-05→ Common Stock (360,508 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2017-03-01$39.75/sh−83,000$3,299,250→ 0 totalExercise: $6.75Exp: 2026-03-04→ Common Stock (83,000 underlying) - Disposition to Issuer
Common Stock
2017-03-01$46.50/sh−83,000$3,859,500→ 0 total - Disposition to Issuer
Restricted Stock Units
2017-03-01$46.50/sh−105,147$4,889,336→ 0 total→ Common Stock (105,147 underlying) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−173,519$8,068,634→ 0 total
Footnotes (6)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
- [F2]These restricted stock units, which by their terms were convertible into common stock of the Issuer on a one-for-one basis, vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
- [F3]These options, which provided that 50% of the shares vested on November 5, 2015, 12.5% of the shares vested on May 5, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
- [F4]These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
- [F5]Each restricted stock unit ("RSU") represented a contingent right to receive one share of CoLucid Pharmaceuticals, Inc. common stock.
- [F6]These restricted stock units, which by their terms were convertible into common stock of the Issuer, vesting on a one-for-one basis as to 50% of the RSUs on November 5, 2015, 12.5% of the RSUs on May 5, 2016, and the remaining RSUs in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
Documents
Issuer
CoLucid Pharmaceuticals, Inc.
CIK 0001348649
Entity typeoperating
Related Parties
1- filerCIK 0001348649
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 12:22 PM ET
- Size
- 15.1 KB